U.K. official sacked over drug lobbying case; Lupin launches generic of Janssen birth control pills in U.S.;

@FiercePharma: Study finds some docs are not strongly recommending HPV vaccines for preteens. FierceVaccines story | Follow @FiercePharma

@EricPFierce: ICYMI: 18 months after the FDA slapped Cadila with a Form 483, it sends a warning letter. Article | Follow @EricPFierce

@CarlyHFierce: UPDATED: Former Valeant CFO Schiller to step in for hospitalized CEO Pearson. Report | Follow @CarlyHFierce

> Isle of Wight health official Paul Jerram has been terminated after an investigation into reports that he was tied to drug companies lobbying NHS staff. Story

> The FDA has posted the warning letter that India's Cadila Healthcare acknowledged last week it had received. Post

> Lupin Pharmaceutical has launched in the U.S. a generic of Janssen's Ortho Tri-Cyclen Lo birth control tablets. Story

> A broad review of health records found no indication that the children of women who take antidepressants during pregnancy are at a higher risk of having autism and related disorders or attention-deficit hyperactivity disorder (ADHD). Report

Medical Device News

@FierceMedDev: Clearside announces positive Phase II results in win for back-of-the-eye drug delivery. FierceDrugDelivery story | Follow @FierceMedDev

@EmilyWFierce: This question has been on my mind for a while. What does the "F" in F. Michael Ball stand for? More | Follow @EmilyWFierce

@VarunSaxena2: Medtronic CEO ambivalent about competing with Google, despite budding robotic surgery rivalry. FierceMedicalDevices story | Follow @VarunSaxena2

> Brain app startup settles with FTC over false product claims. Article

> Benvenue secures $60M in debt and equity to accelerate commercialization of its spinal implants. More

> NEA partner outlines challenging med tech VC landscape heading into 2016. Editor's corner

Biotech News

@FierceBiotech: The scoop on every new drug approved in 2015. Feature | Follow @FierceBiotech

@JohnCFierce: Vtesse gets a BTD on Niemann Pick drug. Release | Follow @JohnCFierce

@DamianFierce: man with lots of money has no regrets about making more of it. More from Bloomberg | Follow @DamianFierce

> Accelerator's $48M biotech project looks to spark the NYC startup scene. Report

> Merck bets up to $595M on Quartet's chronic pain pipeline. News

> Biogen backs Rodin's Alzheimer's efforts in a $500M deal. Story

> Conatus pops on more incremental liver data for its lead drug. Article

Biotech Research News

> Cannabinoid drug reduces epileptic seizures in hard-to-treat children. Item

> CRISPR/Cas9 trifecta: Researchers correct genetic defect that triggers Duchenne muscular dystrophy. Report

> Mayo Clinic researchers tackle age-related stem cell dysfunction and metabolic disease. More

> Gut bacteria plays a big role in regulating impact of anti-inflammatory NSAIDs. Story

> UNC team spotlights Dicer as a new target for brain cancers. Article

Vaccines News

> Study finds some docs are not strongly recommending HPV vaccines for preteens. More

> Bavarian Nordic files for Nasdaq IPO. News

> Emergex to use Midatech nanoparticle tech for vaccines against infectious diseases. Story

> Norway's Bionor tests drug-vaccine combo against HIV. Item

> China approves Sinovac's vaccine for hand, foot and mouth disease. Article

Pharma Marketing News

> Actelion slaps $160K-plus price tag on new PAH med Uptravi. Item

> Native advertising for pharma: Winning format or slippery slope to regulatory headaches? Report

> Boosted by CV data, Lilly's Jardiance grabs market share from J&J, AZ. Story

> FDA sends fewer drug promotion action letters in 2015--but is that a good thing for pharma? More

> Novartis matches respiratory rivals with 'smart inhaler' collaboration. Article

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.